ArticleThe World Allergy Organization journal2026
Characterization of hereditary angioedema population in Argentina: A nationwide study.
Article in The World Allergy Organization journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Data about hereditary angioedema (HAE) from Latin American countries are lacking. Our main objective was to characterize the epidemiology, clinical presentation, and treatment patterns of HAE patients from Argentina at a nationwide level. Methods: A non-interventional, observational, web-based survey was conducted, aimed at physicians treating patients with a confirmed diagnosis of HAE. Data about demographic characteristics, HAE type and family history, clinical pattern, attack frequency and triggers, treatment patterns, and use of validated HAE scores were collected to develop a patient registry. Results: Data from 538 patients submitted by 75 physicians were obtained. Median age was 33 years (IQR:20-46). Most patients were female (58.73%). Median age at presentation of first symptoms was 12 years (IQR:5-18). Median time from presentation to a confirmed diagnosis of HAE was 10 years (IQR:5-18). Most patients had deficiency of C1-INH (HAE-1, 76%). Variants in the Conclusion: Argentine HAE patients share several characteristics with patients from real-world studies, but some findings (time to diagnosis, low LTP rates, relatively high rates of HAE-FXII and a novel, recently characterized form of HAE-DAB2IP) require further research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.